• X4 Pharmaceuticals outlined plans at its virtual investor day to fully enroll 126 patients in the Phase 3 4WARD trial by Q4 2026.
• Topline 4WARD data for mavorixafor in primary chronic neutropenia are expected in Q1 2028.
• Potential U.S. FDA approval for that indication is targeted for late 2028 or early 2029.
• The Phase 2b 4STEPS trial, evaluating G-CSF dose reduction with mavorixafor, targets its first patient visit in Q1 2027.
• Topline 4STEPS data are expected in the first half of 2028; planned enrollment is approximately 25 patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. X4 Pharmaceuticals Inc. published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.